Article
Medicine, Research & Experimental
Shuosha Li, Huabin Hu, Dong Ding, Youwen Zhu, Jin Huang
Summary: The study evaluated the cost-effectiveness of BEC, EC, and CI/CF in patients with BRAF V600E-mutated mCRC after first- and second-line therapy based on BEACON trial outcomes data. Results showed that BEC and EC were not cost-effective regimens for patients with pre-treated mCRC with BRAF V600E mutation.
ADVANCES IN THERAPY
(2021)
Review
Oncology
Shogen Boku, Hironaga Satake, Takashi Ohta, Seiichiro Mitani, Kentaro Kawakami, Yozo Suzuki, Toshihiko Matsumoto, Tetsuji Terazawa, Eiki Yamazaki, Hiroko Hasegawa, Tatsuki Ikoma, Mamoru Uemura, Toshifumi Yamaguchi, Atsushi Naito, Yasunobu Ishizuka, Yukinori Kurokawa, Daisuke Sakai, Hisato Kawakami, Toshio Shimokawa, Toshimasa Tsujinaka, Takeshi Kato, Taroh Satoh, Yoshinori Kagawa
Summary: The BRAF V600E mutation is a poor prognostic factor in colorectal cancer, and there are no clear recommendations for first line therapy for patients with this mutation. A recent study showed that a combination of encorafenib, binimetinib and cetuximab had a higher response rate compared to standard chemotherapy. The ongoing TRESBIEN study aims to evaluate the effectiveness of this combination therapy for patients with early recurrent BRAF V600E-mutated colorectal cancer.
Article
Oncology
Martina Eriksen, Per Pfeiffer, Kristoffer Staal Rohrberg, Christina Westmose Yde, Lone Norgard Petersen, Laurids Ostergaard Poulsen, Camilla Qvortrup
Summary: Patients with BRAF V600E mutated mCRC have a poor prognosis, but BRAF targeted therapy has shown potential for improving survival. This study aims to evaluate the efficacy and tolerability of cetuximab given every second week in combination with encorafenib, and explore the correlation between resistance mechanisms and treatment outcomes.
Article
Oncology
A. Boccaccino, B. Borelli, R. Intini, M. Antista, M. Bensi, D. Rossini, A. Passardi, S. Tamberi, R. Giampieri, L. Antonuzzo, L. Noto, G. Roviello, C. Zichi, M. Salati, A. Puccini, C. Noto, A. Parisi, K. Rihawi, M. Persano, V Crespi, M. Libertini, M. Giordano, R. Moretto, S. Lonardi, C. Cremolini
Summary: This study aimed to evaluate the safety, activity, and efficacy of encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC). The results showed that encorafenib plus cetuximab with or without binimetinib had good efficacy in treating mCRC.
Article
Oncology
A. Boccaccino, B. Borelli, R. Intini, M. Antista, M. Bensi, D. Rossini, A. Passardi, S. Tamberi, R. Giampieri, L. Antonuzzo, L. Noto, G. Roviello, C. Zichi, M. Salati, A. Puccini, C. Noto, A. Parisi, K. Rihawi, M. Persano, V Crespi, M. Libertini, M. Giordano, R. Moretto, S. Lonardi, C. Cremolini
Summary: The study aimed to evaluate the safety, activity, and efficacy of using encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer. The results showed consistent outcomes in terms of safety, activity, and efficacy compared to the BEACON trial. Patients in good general condition and less heavily pretreated are more likely to benefit from the targeted treatment.
Article
Oncology
Shin Kobayashi, Hideaki Bando, Akinobu Taketomi, Takeshi Takamoto, Eiji Shinozaki, Manabu Shiozawa, Hiroki Hara, Kentaro Yamazaki, Koji Komori, Nobuhisa Matsuhashi, Takeshi Kato, Yoshinori Kagawa, Mitsuru Yokota, Eiji Oki, Keigo Komine, Shinichiro Takahashi, Masashi Wakabayashi, Takayuki Yoshino
Summary: This study aims to evaluate the efficacy and safety of a novel triplet regimen in the perioperative period for patients with resectable BRAF V600E mutant colorectal cancer. The triplet regimen includes encorafenib, binimetinib, and cetuximab, administered for 3 cycles each before and after curative resection. The primary endpoint is the 1-year progression-free survival rate, and secondary endpoints include disease-free survival, overall survival, and objective response rate.
Article
Oncology
Zhan Wang, Bao-Dong Qin, Chen-Yang Ye, Miao-Miao Wang, Ling-Yan Yuan, Wei-Ping Dai, Li Sun, Ke Liu, Wen-Xing Qin, Xiao-Dong Jiao, Xing-Nan Li, Yuan-Sheng Zang
Summary: This study evaluated the safety and efficacy of a new protocol using vemurafenib and cetuximab combined with FOLFIRI in patients with BRAF V600E-mutated colorectal cancer. The results showed promising antitumour activity and tolerable toxicity with this combination therapy.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Gastroenterology & Hepatology
Javierd Ros, Nadia Saoudi, Iosune Baraibar, Francesc Salva, Josep Tabernero, Elena Elez
Summary: BRAF-V600E mCRC is a challenging disease, with poor response to standard chemotherapy. However, combining the BRAF inhibitor encorafenib with the anti-epidermal growth factor receptor cetuximab has shown promising results. The BEACON trial has been a significant therapeutic change in this field, and there is ongoing research on biomarkers and novel combinations including BRAF inhibitors with immune checkpoint inhibitors.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2022)
Article
Oncology
Emilie Hafliger, Alessandra Boccaccino, Alexandra Lapeyre-Prost, Audrey Perret, Claire Gallois, Maria Antista, Lorenzo Pilla, Thierry Lecomte, Mario Scartozzi, Emilie Soularue, Lisa Salvatore, Vincent Bourgeois, Massimiliano Salati, David Tougeron, Ludovic Evesque, Jean-Nicolas Vaillant, Reem El-Khoury, Sara Lonardi, Chiara Cremolini, Julien Taieb
Summary: The combination of anti-BRAF and anti-EGFRs shows efficacy in patients with BRAFm mCRC previously treated with an anti-EGFR agent. The results of this retrospective study suggest that this combination could be a valuable treatment option for patients with limited therapeutic alternatives.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Vikas Patel, Istvan Szasz, Viktoria Koroknai, Timea Kiss, Margit Balazs
Summary: Melanoma is the most aggressive form of skin cancer, and therapy using combined BRAF/MEK inhibitors has shown promise in treating patients with specific mutations. Unfortunately, many patients develop drug resistance to this treatment. This study aimed to characterize the molecular background of acquired resistance and identified various changes in gene and protein expression that contribute to drug resistance in melanoma cells.
Article
Oncology
Sanne C. F. A. Huijberts, Mirjam C. Boelens, Rene Bernards, Frans L. Opdam
Summary: Treatment strategies inhibiting BRAF in combination with EGFR have been developed in patients with BRAF(V600E) mutant metastatic colorectal cancer, but intrinsic and secondary resistance remains a challenge. Genetic alterations in the PI3K and upstream receptor tyrosine kinases were mostly associated with intrinsic and acquired resistance. Understanding these alterations might improve response duration with targeted inhibitors.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Gregory J. Riely, Egbert F. Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Anne Tsao, Melissa Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussain, Gregory A. Otterson, Ibiayi Dagogo-Jack, Jonathan W. Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E. Johnson
Summary: The combination of encorafenib and binimetinib showed clinical efficacy and acceptable safety in patients with BRAF(V600E)-mutant metastatic NSCLC.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Pharmacology & Pharmacy
Zaina T. Al-Salama
Summary: Encorafenib in combination with cetuximab has shown significantly longer overall survival, higher response rate, and better tolerability in patients with mCRC and a BRAF V600E mutation who have had prior therapy.
Article
Dermatology
Taku Fujimura, Koji Yoshino, Hiroshi Kato, Yasuhiro Fujisawa, Yoshiyuki Nakamura, Yuki Yamamoto, Kayo Kunimoto, Takamichi Ito, Shigeto Matsushita, Takeo Maekawa, Kentaro Ohuchi, Ryo Amagai, Yusuke Muto, Sadanori Furudate, Yumi Kambayashi, Akira Hashimoto, Setsuya Aiba
Summary: In this study of 22 cases treated with encorafenib plus binimetinib combination therapy for BRAF-mutated advanced melanoma, the objective response rate was high for second-line and beyond therapy, indicating comparable efficacy to first-line targeted therapy. Despite inferior overall survival and progression-free survival compared to previous trials, the combination therapy was well-tolerated, suggesting its potential as a second-line treatment option.
JOURNAL OF DERMATOLOGY
(2021)
Review
Oncology
Matthew Fowler, Helene Tobback, Alice Karuri, Paz Fernandez-Ortega
Summary: Encorafenib, a BRAF inhibitor, in combination with cetuximab, an EGFR inhibitor, has been approved for the treatment of BRAF(V600E)-mutant metastatic colorectal cancer. Nurses play a crucial role in managing the care of these patients, including early identification and management of treatment-related adverse events, as well as educating patients and caregivers about these events.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Oncology
Giandomenico Roviello, Catalano Martina, Costanza Winchler, Irene De Gennaro Aquino, Francesca Papa, Eleonora Buttitta, Gemma Rossi, Lorenzo Antonuzzo
Summary: Ramucirumab plus paclitaxel combination therapy has shown high overall response rate and survival benefits in advanced gastric cancer patients. The initial tumor response is significantly associated with survival outcomes, highlighting the importance of identifying biomarkers to predict response.
JOURNAL OF GASTROINTESTINAL CANCER
(2023)
Article
Oncology
Sebastiano Buti, Chiara Tommasi, Giulia Scartabellati, Ugo De Giorgi, Nicole Brighi, Sara Elena Rebuzzi, Silvia Puglisi, Orazio Caffo, Stefania Kinspergher, Alessia Mennitto, Carlo Cattrini, Matteo Santoni, Elena Verzoni, Alessandro Rametta, Marco Stellato, Andrea Malgeri, Giandomenico Roviello, Massimo de Filippo, Alessio Cortellini, Melissa Bersanelli
Summary: Tyrosine kinase inhibitors (TKIs) are crucial for treating metastatic renal cell carcinoma (mRCC). However, the concurrent use of TKIs with proton-pump inhibitors (PPIs) can have adverse effects on treatment outcomes. A retrospective study in Italy found that the concurrent use of PPIs significantly reduced progression-free survival (PFS) and overall survival (OS) in mRCC patients treated with pazopanib or cabozantinib. Furthermore, PPI use also impacted treatment toxicity and compliance. Therefore, the indiscriminate use of PPIs should be avoided and patients requiring gastroprotective therapy should be carefully selected.
Review
Biochemistry & Molecular Biology
Martina Catalano, Giandomenico Roviello, Raffaella Santi, Donata Villari, Pietro Spatafora, Ilaria Camilla Galli, Francesco Sessa, Francesco Lupo Conte, Enrico Mini, Tommaso Cai, Gabriella Nesi
Summary: This article discusses the role of inflammation in promoting tumorigenesis and cancer progression, emphasizing the importance of chronic inflammation in the development of urological cancers. It also explores how tumor-associated inflammatory tissue may serve as a potential diagnostic marker and therapeutic target for anti-cancer therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Martina Catalano, Daniele Generali, Marta Gatti, Barbara Riboli, Leda Paganini, Gabriella Nesi, Giandomenico Roviello
Summary: Deleterious aberrations in DNA repair genes are actionable in approximately 25% of metastatic castration-resistant prostate cancers (mCRPC) patients. Homology recombination repair (HRR) is frequently altered in prostate cancer, particularly BRCA2 gene. Poly ADP-ribose polymerase inhibitors have shown antitumor activity and improved overall survival in mCRPC patients with somatic and/or germline alterations of HHR. However, the clinical use of liquid biopsy in prostate cancer compared to blood and tissue testing is currently very limited.
FRONTIERS IN ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Daniele Lavacchi, Giandomenico Roviello, Alessia Guidolin, Silvia Romano, Jacopo Venturini, Enrico Caliman, Agnese Vannini, Elisa Giommoni, Elisa Pellegrini, Marco Brugia, Serena Pillozzi, Lorenzo Antonuzzo
Summary: The management of patients with metastatic colorectal cancer (mCRC) involves a continuum of care, with trifluridine/tipiracil and regorafenib being the main treatment options. Fruquintinib, a VEGFR inhibitor, has shown anti-tumor activity in preclinical models and has been approved for chemo-refractory mCRC patients. The phase III FRESCO trial and FRESCO-2 trial demonstrated the efficacy of fruquintinib in heavily pretreated patients, with an advantage in overall survival. This review discusses the clinical development of fruquintinib and its potential impact on the continuum of care for colorectal cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Daniele Lavacchi, Sara Fancelli, Eleonora Buttitta, Gianmarco Vannini, Alessia Guidolin, Costanza Winchler, Enrico Caliman, Agnese Vannini, Elisa Giommoni, Marco Brugia, Fabio Cianchi, Serena Pillozzi, Giandomenico Roviello, Lorenzo Antonuzzo
Summary: Resectable gastric or gastroesophageal (G/GEJ) cancer is a heterogeneous disease with no defined molecularly based treatment strategy. Tailored approaches, such as non-operative management and targeting specific receptors, show promise in perioperative treatment. However, methodological issues need to be addressed for more effective tailored therapy for G/GEJ cancer, and caution is still required in implementing these new treatment concepts.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Federica Cosso, Giandomenico Roviello, Gabriella Nesi, Sonia Shabani, Pietro Spatafora, Donata Villari, Martina Catalano
Summary: Renal cell carcinoma (RCC) is the third most common genitourinary cancer and has significant mortality rates. Adjuvant therapy has been explored, but the results for both tyrosine kinase inhibitors and immune checkpoint inhibitors (ICIs) have been conflicting. Biomarker identification and subgroup analyses are needed to determine which patients can benefit from adjuvant therapy. This review discusses the rationale for adjuvant treatment in RCC and summarizes the current trials and future directions.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
Giovanni Domenico Tebala, Antonio Di Cintio, Francesco Ricci, Stefano Avenia, Roberto Cirocchi, Jacopo Desiderio, Domenico Di Nardo, Salomone Di Saverio, Alessandro Gemini, Maria Chiara Ranucci, Stefano Trastulli, Fabio Cianchi, Marco Scatizzi, Fausto Catena
Summary: The treatment of primary tumors in colorectal cancer with unresectable liver and/or lung metastases but no peritoneal carcinomatosis is still controversial. An online survey was conducted to understand the current attitudes and rationales for resection of the primary tumor (RPT). Most respondents preferred palliative chemotherapy as the first choice and reserve RPT for younger patients with good performance status and emergency situations. Younger age and lower workload were associated with more conservative approaches.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Gabriele Perrone, Luigi Rigacci, Sara Urru, Sofya Kovalchuk, Marco Brugia, Alberto Fabbri, Lorenzo Iovino, Benedetta Puccini, Emanuele Cencini, Enrico Orciuolo, Silvia Birtolo, Alessandro Melosi, Simone Santini, Ida Landini, Giandomenico Roviello, Raffaella Santi, Alessandra Macciotta, Fulvio Ricceri, Alberto Bosi, Monica Bocchia, Mario Petrini, Enrico Mini, Stefania Nobili
Summary: This study aimed to explore the constitutional biomarkers predictive of R-CHOP efficacy and toxicity in DLBCL patients. Significant associations were found between six SNPs and progression-free survival (PFS), and five SNPs and overall survival (OS). These SNPs, after validation in an independent cohort, could improve the prediction of R-CHOP response.
Article
Oncology
Francesco Giudici, Laura Fortuna, Edda Russo, Benedetta Badii, Francesco Coratti, Fabio Staderini, Alessio Morandi, Clotilde Sparano, Luisa Petrone, Fabio Cianchi, Giuliano Perigli
Summary: This study describes a case series of sporadic primary hyperparathyroidism treated by a single operator in a dedicated database. The use of intraoperative PTH may not be beneficial for surgeons in primary operations when ultrasound and scintiscan are concordant. Not using intraoperative PTH is not only cost-effective but also reduces operating time, anesthesia time, and hospital stays.
Correction
Biochemistry & Molecular Biology
Alberto D'Angelo, Kensuke Shibata, Masayuki Tokunaga, Makoto Furutani-Seiki, Stefan Bagby
BIOCHEMISTRY AND BIOPHYSICS REPORTS
(2023)
Article
Urology & Nephrology
Simone Sforza, Valeria Emma Palmieri, Maria Rosaria Raspollini, Giandomenico Roviello, Alberto Mantovani, Umberto Basso, Maria Carmen Affinita, Alberto D'Angelo, Lorenzo Antonuzzo, Marco Carini, Andrea Minervini, Lorenzo Masieri
Summary: This study reviewed the literature on robotic surgery in Wilms' tumor and reported the first case of adult WT management using both neoadjuvant chemotherapy and robotic strategy.
ASIAN JOURNAL OF UROLOGY
(2023)
Review
Oncology
Martina Catalano, Andrea Lapucci, Stefania Nobili, Irene De Gennaro Aquino, Ismaela Anna Vascotto, Lorenzo Antonuzzo, Donata Villari, Gabriella Nesi, Enrico Mini, Giandomenico Roviello
Summary: Metastatic prostate cancer is a significant global health burden, and effective treatment strategies are continuously being developed. Recent studies have shown that mutations in DNA repair genes are prevalent in these patients, making them more responsive to platinum-based chemotherapy and PARP inhibitors. Combining platinum-based chemotherapy with PARP inhibitors may be a novel therapeutic strategy for this patient population.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2023)
Article
Oncology
Xiaofan Pu, Chaolei Zhang, Guoping Ding, Hongpeng Gu, Yang Lv, Tao Shen, Tianshu Pang, Liping Cao, Shengnan Jia
Summary: This study demonstrated the potential utility of the sEV-miRNA d-signature in the diagnosis of PDAC via machine learning methods. A novel sEV biomarker, miR-664a-3p, was identified for the diagnosis of PDAC. It can also potentially promote angiogenesis and metastasis, provide insight into PDAC pathogenesis, and reveal novel regulators of this disease.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Jiaping Wang, Zhijuan Xu, Yanli Lai, Yanli Zhang, Ping Zhang, Qitian Mu, Shujun Yang, Yongcheng Sun, Lixia Sheng, Guifang Ouyang
Summary: This study demonstrates the significance of PD-1 in EBV-infected lymphoma cells. Silencing PD-1 enhances the tumor targeting effect of EBV-specific killer T cells on B lymphocytes and attenuates the immune escape effect.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Qiliang Peng, Jialong Tao, Yingjie Xu, Yi Shen, Yong Wang, Yang Jiao, Yiheng Mao, Yaqun Zhu, Yulong Liu, Ye Tian
Summary: This study investigates the potential role of lipid metabolism-associated genes (LMAGs) in neoadjuvant chemoradiotherapy (nCRT) and immunotherapy for rectal cancer. The results suggest that the SREBF2 gene is a highly predictive factor for nCRT in rectal cancer and is associated with favorable prognosis. SREBF2 is also closely associated with immune cell infiltration and immunotherapy-related genes.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Shiquan Li, Nan Zhang, Yongping Yang, Tongjun Liu
Summary: This study investigated the potential molecular mechanism of SPDEF in immune evasion of colorectal cancer (CRC) and found that it suppresses immune evasion by activating CCL28 through the modulation of M2 polarization of macrophages. These findings provide a new research direction and potential therapeutic target for immunotherapy in CRC.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Manas Sehgal, Soundharya Ramu, Joel Markus Vaz, Yogheshwer Raja Ganapathy, Srinath Muralidharan, Sankalpa Venkatraghavan, Mohit Kumar Jolly
Summary: This study investigates the relationship between gene expression patterns and phenotypic plasticity and heterogeneity in colorectal cancer (CRC). The results demonstrate the interconnectedness between different Consensus Molecular Subtypes (CMS) of CRC and specific phenotypes such as epithelial and mesenchymal characteristics. Additionally, the study reveals correlations between metabolic pathways and phenotypic scores, as well as between PD-L1 activity and mesenchymal phenotype. Single-cell RNA sequencing analysis further confirms the heterogeneity of different CMS subtypes. These findings have important implications for understanding CRC heterogeneity and developing targeted therapies.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Yutong Zou, Siyao Guo, Yan Liao, Weidong Chen, Ziyun Chen, Junkai Chen, Lili Wen, Xianbiao Xie
Summary: This study found that ceramide metabolism is associated with the progression and clinical outcome of osteosarcoma by analyzing data from osteosarcoma patients. The gene ST3GAL1 plays an important role in osteosarcoma, regulating the tumor immune microenvironment and affecting T cell function. It may become a new target for the treatment of osteosarcoma.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Chuanhui Chen, Mengzhi Wan, Xiong Peng, Qing Zhang, Yu Liu
Summary: This study examines the function and mechanism of the ceRNA network centered around GPR37 in LUAD. The findings show that high expression of GPR37 in LUAD tissue samples is associated with poor prognosis, and it may regulate the expression of downstream target genes by competitively binding to lncRNA DLEU1 and miR-4458.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Junping Li, Hong Hu, Jinping He, Yuling Hu, Manting Liu, Bihui Cao, Dongni Chen, Xiaodie Ye, Jian Zhang, Zhiru Zhang, Wen Long, Hui Lian, Deji Chen, Likun Chen, Lili Yang, Zhenfeng Zhang
Summary: Sequential administration of CDC7 inhibitor XL413 after carboplatin enhances the chemotherapeutic effect of carboplatin on ovarian cancer cells, possibly by inhibiting homologous recombination repair activity and increasing the accumulation of chemotherapy-induced DNA damage.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Madison Catalanotto, Joel Markus Vaz, Camille Abshire, Reneau Youngblood, Min Chu, Herbert Levine, Mohit Kumar Jolly, Ana -Maria Dragoi
Summary: The study demonstrates that loss of FLASH in cancer cells leads to a hybrid E/M phenotype with high epithelial scores, suggesting FLASH acts as a repressor of the epithelial phenotype. Additionally, FLASH expression is inversely correlated with the epithelial score and subsets of mesenchymal markers are distinctly up-regulated in FLASH, NPAT, or SLBP-depleted cells.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Xiaorui Wang, Na Li, Minying Zheng, Yongjun Yu, Shiwu Zhang
Summary: Adipocytes are derived from pluripotent mesenchymal stem cells and histone modifications play a key role in their differentiation. Recent studies have shown that cancer stem cells can differentiate into adipocytes, reducing the malignancy of cancer cells.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Hana Q. Sadida, Alanoud Abdulla, Sara Al Marzooqi, Sheema Hashem, Muzafar A. Macha, Ammira S. Al-Shabeeb Akil, Ajaz A. Bhat
Summary: Cancer heterogeneity and drug resistance are major obstacles to effective cancer treatment, and epigenetic modifications play a pivotal role in these processes. This review explores essential epigenetic modifications, including DNA methylation, histone modifications, and chromatin remodeling, and discusses their complex contributions to cancer biology. However, the interplay of epigenetic and genetic changes in cancer cells presents unique challenges that must be addressed to fully exploit the potential of epigenetic modifications.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Pedro De Marchi, Leticia Ferro Leal, Luciane Sussuchi da Silva, Rodrigo de Oliveira Cavagna, Flavio Augusto Ferreira da Silva, Vinicius Duval da Silva, Eduardo C. A. da Silva, Augusto O. Saito, Vladmir C. Cordeiro de Lima, Rui Manuel Reis
Summary: The TIS and IFN-gamma signatures are predictive biomarkers for identifying NSCLC patients who could potentially benefit from immune checkpoint inhibitor therapies.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Giovanni Marchi, Anna Rajavuori, Mai T. N. Nguyen, Kaisa Huhtinen, Sinikka Oksa, Sakari Hietanen, Sampsa Hautaniemi, Johanna Hynninen, Jaana Oikkonen
Summary: The study shows that ctDNA can adequately represent high-grade serous ovarian carcinoma (HGSC), and the mutations observed at relapse suggest personalized therapy options.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Yuncang Yuan, Jiawei Fan, Dandan Liang, Shijie Wang, Xu Luo, Yongjie Zhu, Nan Liu, Tingxiu Xiang, Xudong Zhao
Summary: This study demonstrates that csGRP78-directed CAR-T cells can selectively kill pancreatic cancer cells, and the combination with chemotherapy enhances cytotoxicity.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Niyati Piplani, Tanusri Roy, Neha Saxena, Shamik Sen
Summary: The glycocalyx, a protective barrier surrounding cells, has been found to play a role in cancer cell proliferation, survival, and metastasis. However, its function in maintaining DNA/nuclear integrity during migration through dense matrices has not been explored. This study shows that the bulkiness of the glycocalyx is inversely associated with nuclear stresses, and highlights its mechanical role in shielding migration-associated stresses.
TRANSLATIONAL ONCOLOGY
(2024)
